

6. Martin RJ, Bel EH, Pavord ID et al. Defining severe obstructive lung disease in the biological era: an endotype-based approach. *Eur Respir J*. 2019; 54: 1900108.
7. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2016; 138(1): 16–27.
8. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 335–349.
9. Singh D, Kolsum U, Brightling CE et al. ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J*. 2014; 44(6): 1697–700.
10. Polosukhin VV, Richmond BW, Du RH et al. Secretory IgA Deficiency in Individual Small Airways Is Associated with Persistent Inflammation and Remodeling. *Am J Respir Crit Care Med*. 2017; 195(8): 1010–1021.
11. McDonough JE, Yuan R, Suzuki M et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med*. 2011; 365(17): 1567–1575.
12. Elbehairy AF, Ciavaglia CE, Webb KA et al. Canadian Respiratory Research Network. Pulmonary Gas Exchange Abnormalities in Mild Chronic Obstructive Pulmonary Disease. Implications for Dyspnea and Exercise Intolerance. *Am J Respir Crit Care Med*. 2015; 191(12): 1384–1394.
13. Garcia-Rio F, Miravittles M, Soriano JB et al. EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. *Respir Res*. 2010; 11: 63.
14. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. *Clin Transl Med*. 2015; 4(1): 68.
15. Kim HC, Mofarrah M, Hussain SN. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2008; 3(4): 637–658.
16. Chen YW, Ramsook AH, Coxson HO et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis. *Chest*. 2019; 156(6): 1092–1110.
17. Lu Y, Feng L, Feng L et al. Systemic inflammation, depression and obstructive pulmonary function: a population-based study. *Respir Res*. 2013; 14: 53.
18. Hersh CP, Make BJ, Lynch DA et al.; COPDGene and ECLIPSE Investigators. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. *BMC Pulm Med*. 2014; 14: 164.
19. Agusti A, Bel E, Thomas M et al. Treatable traits: toward precision medicine of chronic airway diseases. *Eur Respir J*. 2016; 47(2): 410–419.
20. Franssen FM, Alter P, Bar N et al. Personalized medicine for patients with COPD: where are we? *Int J Chron Obstruct Pulmon Dis*. 2019; 14: 1465–1484.
21. Bigna JJ, Kenne AM, Asangbeh SL et al. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. *Lancet Glob Health*. 2018; 6(2): e193–e202.
22. Bui DS, Burgess JA, Lowe AJ et al. Childhood Lung Function Predicts Adult Chronic Obstructive Pulmonary Disease and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. *Am J Respir Crit Care Med*. 2017; 196(1): 39–46.
23. Broström EB, Akre O, Katz-Salomon M et al. Obstructive pulmonary disease in old age among individuals born preterm. *Eur J Epidemiol*. 2013; 28(1): 79–85.
24. Byrne AL, Marais BJ, Mitnick CD et al. Tuberculosis and chronic respiratory disease: a systematic review. *Int J Infect Dis*. 2015; 32: 138–146.
25. Hayden LP, Hobbs BD, Cohen RT et al.; COPDGene Investigators. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. *Respir Res*. 2015; 16: 115.
26. Greulich T, Nell C, Hohmann D et al. The prevalence of diagnosed α 1-antitrypsin deficiency and its comorbidities: results from a large population-based database. *Eur Respir J*. 2017; 49(1): 1600154.
27. Guo F, Kuang JL. Superoxide dismutase gene polymorphisms and functional activity in chronic obstructive pulmonary disease. *Zhonghua Jie He He Hu Xi Za Zhi*. 2011; 34(6): 424–428.
28. Houghton AM. Matrix metalloproteinases in destructive lung disease. *Matrix Biol*. 2015; 44–46: 167–174.
29. Ding Z, Wang K, Li J et al. Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: A meta-analysis. *Clin Genet*. 2019; 95(1): 53–62.
30. Miravittles M, Dirksen A, Ferrarotti I et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α (1)-antitrypsin deficiency. *Eur Respir J*. 2017; 50(5): 1700610.
31. Burgel PR, Laurendeau C, Raheison C et al. An attempt at modeling COPD epidemiological trends in France. *Respir Res*. 2018; 19(1): 130.
32. Adeloye D, Chua S, Lee C et al.; Global Health Epidemiology Reference Group (HERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. *J Glob Health*. 2015; 5(2): 020415.
33. Koblizek V, Jarkovsky J, Dusek L, Benesova K, Svoboda M, Brat K. The Czechia COPD mortality rate declining, but total deaths increasing. *Eur Respir J* 2020; 56(suppl 64): 434.
34. Vondra V, Malý M. Výrazný vzestup úmrtnosti na chronickou obstrukční plicní nemoc v České republice v letech 2013–2017. *Studia Pneumol Phthiseol*. 2019; 79(2): 43–50.
35. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*. 2004; 350(10): 1005–1012.
36. Puhan MA, Garcia-Aymerich J, Frey M et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. *Lancet*. 2009; 374(9691): 704–711.
37. Brat K, Svoboda M, Hejduk K et al. Introducing a new prognostic instrument for long-term mortality prediction in COPD patients: the CADOT index. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2020; in press. doi: 10.5507/bp.2020.035.
38. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. *Ann Intern Med*. 2011; 155(3): 179–191.
39. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005; 26(5): 948–968.
40. Brat K, Plutinsky M, Hejduk K et al. Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 1037–1052.
41. Agusti A. The path to personalised medicine in COPD. *Thorax*. 2014; 69(9): 857–864.
42. Le Rouzic O, Roche N, Cortot AB et al. Defining the „Frequent Exacerbator“ Phenotype in COPD: A Hypothesis-Free Approach. *Chest*. 2018; 153(5): 1106–1115.
43. Chalmers JD, Aliberti S, Filonenko A et al. Characterization of the „Frequent Exacerbator Phenotype“ in Bronchiectasis. *Am J Respir Crit Care Med*. 2018; 197(11): 1410–1420.
44. Koblizek V, Milenkovic B, Barczyk A et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. *Eur Respir J*. 2017; 49(5): 1601446.
45. Kim V, Han MK, Vance GB et al.; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. *Chest*. 2011; 140(3): 626–633.
46. Cheng Y, Tu X, Pan L et al. Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. *Int J Chron Obstruct Pulmon Dis*. 2017; 12: 2069–2074.
47. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge. *Respirology*. 2016; 21(3): 410–418.
48. Takiguchi H, Asano K. Asthma-COPD overlap syndrome (ACOS). *Nihon Rinsho*. 2016; 74(5): 778–782.
49. Martinez-Garcia MA, Miravittles M. Bronchiectasis in COPD patients: more than a comorbidity? *Int J Chron Obstruct Pulmon Dis*. 2017; 12: 1401–1411.
50. Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. *Eur Respir J*. 2018; 52(3): 1800328.
51. Yu Q, Peng H, Li B et al. Characteristics and related factors of bronchiectasis in chronic obstructive pulmonary disease. *Medicine (Baltimore)*. 2019; 98(47): e17893.
52. Sánchez-Muñoz G, Lopez-de-Andrés A, Hernández-Barrera V et al. Bronchiectasis in patients hospitalized with acute exacerbation of COPD in Spain: Influence of mortality, hospital stay, and hospital costs (2006–2014) according to gender. *PLoS One*. 2019; 14(1): e0211222.
53. McDonald MN, Wouters EFM, Rutten E et al. It's more than low BMI: prevalence of cachexia and associated mortality in COPD. *Respir Res*. 2019; 20(1): 100.
54. Kwan HY, Maddocks M, Nolan CM et al. The prognostic significance of weight loss in chronic obstructive pulmonary disease – related cachexia: a prospective cohort study. *J Cachexia Sarcopenia Muscle*. 2019; 10(6): 1330–1338.
55. Mokari-Yamchi A, Jabbari M, Sharifi A et al. Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients. *Int J Chron Obstruct Pulmon Dis*. 2019; 14: 2433–2440.
56. Sanchez FF, Faganello MM, Tanni SE et al. Anthropometric midarm measurements can detect systemic fat-free mass depletion in patients with chronic obstructive pulmonary disease. *Braz J Med Biol Res*. 2011; 44(5): 453–459.
57. Brat K, Svoboda M, Zatloukal J, Plutinsky M, Volakova E, Popelkova P, Novotna B, Dvorak T, Koblizek V. The relation between clinical phenotypes, GOLD groups/stages and mortality in COPD patients - a prospective multicenter study. *Int J Chron Obstruct Pulmon Dis*. 2021; in press.
58. Ajmera M, Sambamoorthi U, Metzger A et al. Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD. *Respir Care*. 2015; 60(11): 1592–1602.
59. Jantunen J, Haahtela T, Salimäki J et al. Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey. *Int Arch Allergy Immunol*. 2019; 179(4): 273–280.
60. Spyrtos D, Haidich AB, Chloros D et al. COPD screening program: What is appropriate target group population? *Respiration*. 2017; 94(1): 74.
61. Ulrik CS, Løkke A, Dahl R et al., TOP study group. Early detection of COPD in general practice. *Int J Chron Obstruct Pulmon Dis*. 2011; 6: 123–127.
62. Jiménez-Ruiz CA, Andreas S, Lewis KE et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. *Eur Respir J*. 2015; 46(1): 61–79.

Další literatura u autora
a na www.casopisvnitrnilekarstvi.cz